Non-Active SPMS clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for

  • IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

    Sorry, not yet accepting patients

    This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.

    San Francisco, California and other locations

Last updated: